Charles Schwab Investment Management Inc Cogent Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 833,155 shares of COGT stock, worth $6.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
833,155
Previous 825,793
0.89%
Holding current value
$6.39 Million
Previous $8.92 Million
27.14%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding COGT
# of Institutions
190Shares Held
104MCall Options Held
157KPut Options Held
439K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$69.8 Million4.5% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$55.9 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$53.4 Million8.87% of portfolio
-
Commodore Capital LP New York, NY6.88MShares$52.8 Million5.38% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$47.8 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $504M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...